Skip to content

Efficacy and Safety of A0001 for Anterior Capsule Staining: Phase III Investigator-initiated Multicenter Clinical Trial

Efficacy and Safety of A0001 for Anterior Capsule Staining: Phase III Investigator-initiated Multicenter Clinical Trial - Efficacy and Safety of A0001 for Anterior Capsule Staining

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028386
Enrollment
30
Registered
2017-08-07
Start date
2017-09-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory cataract

Interventions

Brilliant Blue G250

Sponsors

Kyushu University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: There are indications for cataract surgery for one eye or both eyes, and cataract with severe cortical cataract, mature cataract, hyperzagmus cataract, cataract with corneal opacity, cataract with vitreous opacity, etc. Cataract in which it is difficult to see the anterior capsule of the lens in normal cataract surgery.

Exclusion criteria

Exclusion criteria: 1) IOL implanted eye. 2) Has serious of digestive, circulatory, kidney, liver, or blood/coagulation complications 3) Had present and past uveitis or glaucoma 4) Those who fall under Grade 3 or Grade 4 in the classification of "Grading for Corneal Endothelial Damage (2014) "prescribed by the Japan Corneal Society. However, cases where it is difficult to measure the number of corneal endothelial cells by corneal clouding or the like can be incorporated. 5) Patient of Bullous keratopathy 6) Has a history of drug hypersensitivity reactions for mydriatic, antibacterial eyedrops or local anesthetic. 7) Has a history of drug or alcohol abuse 8) Had taken this clinical trial 9) Those who participated in other clinical trials or clinical studies within 30 days before consent acquisition and received medication, or those planning to participate in other trials during this trial 8) Is deemed unsuitable for this trial by PI or SI

Design outcomes

Primary

MeasureTime frame
Central evaluation of the efficacy of A0001 administered to anterior camber for visualization of the anterior capsule during cataract surgery.

Secondary

MeasureTime frame
-Evaluation of degree of visualization and evaluation of ease of operation by surgeon. -Evaluation of the safety of A0001 based on data of adverse effects, side effects, ophthalmological examinations.

Countries

Japan

Contacts

Public ContactMakiko Uchiyama

Kyushu University Hospital Center for Clinical and Translational Research

m-uchi@med.kyushu-u.ac.jp092-642-6291

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026